12 Health Care Stocks Moving In Friday's After-Market Session

[ad_1]

Gainers

  • Biofrontera BFRI shares increased by 18.5% to $2.24 during Friday’s after-market session. Today’s trading volume for this security ended up closing at 1.9 million shares, which is 397.5 percent of its average volume over the last 100 days. The company’s market cap stands at $42.4 million.
  • Revelation Biosciences REVB stock moved upwards by 10.75% to $0.72. The company’s market cap stands at $10.8 million.
  • IsoPlexis ISO stock rose 10.31% to $3.53. The market value of their outstanding shares is at $137.9 million.
  • Heart Test Laboratories HSCS stock moved upwards by 9.09% to $1.32. The market value of their outstanding shares is at $10.6 million.
  • Belite Bio BLTE stock increased by 8.14% to $43.0. The company’s market cap stands at $1.0 billion.
  • Stealth BioTherapeutics MITO shares moved upwards by 6.67% to $0.25. The company’s market cap stands at $18.6 million.

Losers

  • Nymox Pharmaceutical NYMX stock fell 9.6% to $0.31 during Friday’s after-market session. The company’s market cap stands at $27.7 million.
  • Addex Therapeutics ADXN stock decreased by 9.1% to $1.8. This security traded at a volume of 1.5 million shares come close, making up 60.5% of its average volume over the last 100 days. The company’s market cap stands at $11.3 million.
  • Exicure XCUR shares fell 8.55% to $1.82. The company’s market cap stands at $9.0 million.
  • Pasithea Therapeutics KTTA stock declined by 7.21% to $1.07. The company’s market cap stands at $24.9 million.
  • Citius Pharmaceuticals CTXR shares fell 6.41% to $0.92. Today’s trading volume for this security ended up closing at 74.3K shares, which is 4.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $134.4 million.
  • Cosmos Holdings COSM shares decreased by 6.07% to $0.37. The market value of their outstanding shares is at $6.9 million.
    See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.